tradingkey.logo
tradingkey.logo
Suchen

Bluejay Diagnostics Inc

BJDX
Zur Watchlist hinzufügen
1.140USD
-0.060-5.00%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
172.29KMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Bluejay Diagnostics Inc Unternehmen

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.

Bluejay Diagnostics Inc Informationen

BörsenkürzelBJDX
Name des UnternehmensBluejay Diagnostics Inc
IPO-datumNov 10, 2021
CEODey (Neil)
Anzahl der mitarbeiter7
WertpapierartOrdinary Share
GeschäftsjahresendeNov 10
Addresse360 Massachusetts Avenue, Suite 203
StadtACTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01720
Telefon19786310152
Websitehttps://bluejaydx.com/
BörsenkürzelBJDX
IPO-datumNov 10, 2021
CEODey (Neil)

Führungskräfte von Bluejay Diagnostics Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
12.52K
-0.01%
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
12.50K
-0.01%
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
12.52K
-0.01%
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
12.50K
-0.01%
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Bluejay Diagnostics Inc?

Die fünf größten Anteilseigner von Bluejay Diagnostics Inc sind: Mr. Donald R. Chase

Wie viele Institutionen halten Anteile an Bluejay Diagnostics Inc (BJDX)?

Mit Stand vom 2026Q1 halten 20 Institutionen Anteile an Bluejay Diagnostics Inc, mit einem Gesamtmarktwert von etwa 42.23K, was 4.08% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 12914.00 gestiegen.